Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab influence outcomes and drug levels in IBD

January's issue of the American Journal of Gastroenterology reviews the impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with IBD.

News image

Antibodies to infliximab have been associated with loss of clinical response and lower serum infliximab levels in some studies of patients with inflammatory bowel disease (IBD).

This has important implications for patient management and development of novel biologic therapies.

Dr Kavinderjit Nanda from Massachusetts, USA performed a systematic review and meta-analysis of studies that reported clinical outcomes and infliximab levels according to patients’ Antibodies to infliximab status.

MEDLINE, Web of Science, CINAHL, Scopus, and EMBASE were searched for eligible studies.

The researchers reported quality assessment was undertaken using GRADE criteria.

Raw data from studies meeting inclusion criteria was pooled for meta-analysis of effect estimates.

Sensitivity analysis was performed for all outcomes.

The team of doctors reported that a funnel plot was performed to assess for publication bias.

The team identified 13 studies that met the inclusion criteria, and reported results in 1,378 patients with inflammatory bowel disease.

All included studies had a high risk of bias in at least 1 quality domain.

The team of researchers found that the pooled risk ratio of loss of clinical response to infliximab in patients with IBD who had antibodies to infliximab was 3.2, when compared with patients without antibodies to infliximab.

This effect estimate was predominantly based on data from patients with Crohn's disease.

The doctors found that data only from patients with ulcerative colitis exhibited a non-significant relative risk of loss of response of 2.2 in those with antibodies to infliximab.

The standardized mean difference in trough serum infliximab levels between groups was −0.8
American Journal of Gastroenterology

Heterogeneity existed between studies, in both methods of antibodies to infliximab detection, and clinical outcomes reported.

The team observed that 3 studies reported trough serum infliximab levels according to antibodies to infliximab status.

The standardized mean difference in trough serum infliximab levels between groups was −0.8.

A funnel plot suggested the presence of publication bias.

Dr Nanda's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of loss of clinical response to infliximab and lower serum infliximab levels in patients with inflammatory bowel disease."

"Published studies on this topic lack uniform reporting of outcomes."

"High risk of bias was present in all the included studies."

Am J Gastroenterol 2013; 108:40–47
15 January 2013

Go to top of page Email this page Email this page to a colleague

 29 August 2014

Advanced search
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 28 August 2014 
Predictoris of C. diff in out-patients
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease
 22 August 2014 
Outlier identification in colorectal surgery
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials
 21 August 2014 
Screening for Barrett’s esophagus
 21 August 2014 
Colorectal cancer mortality in Brazil
 21 August 2014 
Eosinophilic esophagitis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions
 18 August 2014 
The evolution of urban C. difficile
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 15 August 2014 
Population-based fecal immunochemical test screening
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Fecal immunochemical test screening
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Flexible sigmoidoscopy screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 08 August 2014 
Surgeon volume and esophagectomy survival
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD
 05 August 2014 
Rising incidence of celiac disease
 05 August 2014 
Socioeconomic status and IBS
 05 August 2014 
Bowel dysfunction after sphincter-preserving rectal cancer surgery
 04 August 2014 
Relative adrenal insufficiency and chronic liver disease
 04 August 2014 
Colonoscopy screening protocol for liver transplant recipients
 04 August 2014 
Patient-reported outcomes after upper GI bleed

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us